-
公开(公告)号：US11911389B2
公开(公告)日：2024-02-27
申请号：US18053478
申请日：2022-11-08
发明人： Jin Jean Wang , Gerald J. Yakatan , Ting N. Lin , Jing H. Gao
IPC分类号： A61K31/522 , A61K31/137 , A61K31/4402 , A61K31/4422 , A61K31/455 , A61K31/46 , A61K31/575 , A61P9/06
CPC分类号： A61K31/522 , A61K31/137 , A61K31/4402 , A61K31/4422 , A61K31/455 , A61K31/46 , A61K31/575 , A61P9/06
摘要： Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist.
-
公开(公告)号：US11491159B2
公开(公告)日：2022-11-08
申请号：US17008538
申请日：2020-08-31
发明人： Jin Jean Wang , Gerald J. Yakatan , Ting N. Lin , Jing H. Gao
IPC分类号： A61K31/522 , A61K31/4422 , A61K31/4402 , A61P9/06 , A61K31/575 , A61K31/455 , A61K31/46 , A61K31/137
摘要： Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist.
-
公开(公告)号：US20190231786A1
公开(公告)日：2019-08-01
申请号：US16353675
申请日：2019-03-14
发明人： Jin Jean Wang , Gerald J. Yakatan , Ting N. Lin , Jing H. Gao
IPC分类号： A61K31/522 , A61K31/137 , A61K31/46 , A61K31/455 , A61K31/4422 , A61P9/06 , A61K31/4402 , A61K31/575
摘要： Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist.
-
4.发明公开公开(公告)号：US20240285639A1
公开(公告)日：2024-08-29
申请号：US18630064
申请日：2024-04-09
发明人： Jin Jean Wang , Gerald J. Yakatan
IPC分类号： A61K31/522 , A61K31/137 , A61K31/4402 , A61K31/4422 , A61P9/00
CPC分类号： A61K31/522 , A61K31/137 , A61K31/4402 , A61K31/4422 , A61P9/00
摘要： Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine H1-receptor agonist, a histamine H2-receptor agonist, or a histamine H3-receptor antagonist, and (iv) a β2-adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.
-
公开(公告)号：US20240207279A1
公开(公告)日：2024-06-27
申请号：US18420659
申请日：2024-01-23
发明人： Jin Jean Wang , Gerald J. Yakatan , Ting N. Lin , Jing H. Gao
IPC分类号： A61K31/522 , A61K31/137 , A61K31/4402 , A61K31/4422 , A61K31/455 , A61K31/46 , A61K31/575 , A61P9/06
CPC分类号： A61K31/522 , A61K31/137 , A61K31/4402 , A61K31/4422 , A61K31/455 , A61K31/46 , A61K31/575 , A61P9/06
摘要： Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist.
-
6.发明申请公开(公告)号：US20190070184A1
公开(公告)日：2019-03-07
申请号：US16178257
申请日：2018-11-01
发明人： Jin Jean Wang , Gerald J. Yakatan
IPC分类号： A61K31/522 , A61K31/137 , A61K31/4422 , A61K31/4402 , A61P9/00
摘要： Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine H1-receptor agonist, a histamine H2-receptor agonist, or a histamine H3-receptor antagonist, and (iv) a β2-adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.
-
公开(公告)号：US20220184089A1
公开(公告)日：2022-06-16
申请号：US17689576
申请日：2022-03-08
发明人： Jin Jean Wang , Gerald J. Yakatan , Ting N. Lin , Jing H. Gao
IPC分类号： A61K31/522 , A61K31/4422 , A61K31/4402 , A61P9/06 , A61K31/575 , A61K31/455 , A61K31/46 , A61K31/137
摘要： Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist.
-
公开(公告)号：US11266651B2
公开(公告)日：2022-03-08
申请号：US15973132
申请日：2018-05-07
发明人： Jin Jean Wang , Gerald J. Yakatan , Ting N. Lin , Jing H. Gao
IPC分类号： A61K31/522 , A61K31/4422 , A61K31/4402 , A61P9/06 , A61K31/575 , A61K31/455 , A61K31/46 , A61K31/137
摘要： Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist.
-
公开(公告)号：US10758544B2
公开(公告)日：2020-09-01
申请号：US16353675
申请日：2019-03-14
发明人： Jin Jean Wang , Gerald J. Yakatan , Ting N. Lin , Jing H. Gao
IPC分类号： A61K31/522 , A61K31/4422 , A61K31/4402 , A61P9/06 , A61K31/575 , A61K31/455 , A61K31/46 , A61K31/137
摘要： Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a β2-adrenoreceptor agonist.
-
公开(公告)号：US11951107B2
公开(公告)日：2024-04-09
申请号：US18059924
申请日：2022-11-29
发明人： Jin Jean Wang , Gerald J. Yakatan
IPC分类号： A61K31/522 , A61K31/137 , A61K31/4402 , A61K31/4422 , A61P9/00
CPC分类号： A61K31/522 , A61K31/137 , A61K31/4402 , A61K31/4422 , A61P9/00
摘要： Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine H1-receptor agonist, a histamine H2-receptor agonist, or a histamine H3-receptor antagonist, and (iv) a β2-adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.016 秒)
